Accurexa revealed the launch of an agreement to develop its stem cell-mediated immunotherapy for the treatment of cancer, including brain cancer, in collaboration with StemImmune. StemImmune's immunotherapy reportedly uses the stealth anti-cancer payload carrying and tumor seeking capacities of a patient's own readily available (adult) stem cells to target cancer. The patient's immune system cannot recognize and react to the 'Trojan Horse' stem cells, because they are the patient's own. In conjunction, Accurexa is developing its ACX-31 programme for the local delivery of temozolomide as adjunctive therapy to BCNU, both chemotherapeutics, to brain tumor sites. Oral temozolomide is a generic, US FDA approved, first-line chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.